{"disease":{"id":"lal-deficiency","name":"lal deficiency"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT01633489","title":"Lysosomal Acid Lipase (LAL) Deficiency Registry","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04375592","title":"Acceptability and Tolerance of a Ready-to-use Protein Substitute in Tablet Form for the Dietary Management of Phenylketonuria","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"metaX Institut fuer Diatetik GmbH","has_results":false},{"nct_id":"NCT01307098","title":"Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01488097","title":"Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}